Heart Failure

Multiple comorbidities lead to an emphasis on multidisciplinary care management when determining the most effective HF treatment strategies.

Russell Rotondo, MD, FACC, medical director of clinical strategy and innovation for cardiology at Cohere Health, discusses the myriad positive ways utilization management programs can have an impact on patient outcomes in cardiovascular care.

Amresh Raina, MD, is director of the Advanced Heart Failure and Pulmonary Hypertension Program at Allegheny General Hospital and the Allegheny Health Network in Pittsburgh, Pennsylvania.

This study investigated long-term mortality outcomes following transcatheter aortic valve replacement (TAVR) among patients with a left ventricular ejection fraction (LVEF) below 50% and comorbid severe aortic stenosis.

This new study investigated risk factors for cardiovascular disease, including heart failure, among hospitalized patients with a recent history of methamphetamine use and priority patient populations to target.

People who experienced childhood poverty and other adversities are at greater risk of premature death in adulthood; Pfizer’s COVID-19 vaccine is 73% effective in protecting children younger than 5 years; women experience more symptoms of heart failure and other cardiovascular diseases than men.

This subanalysis of data from the ELDERCARE-AF trial investigated the safety and effectiveness of a 15-mg daily dose of the factor Xa inhibitor among older patients who have atrial fibrillation (AFib).

Entresto (sacubitril/valsartan) is approved for use in adult and pediatric heart failure, and previous research shows it to be cost-effective in the long term.

The REVEAL-HF study investigated using risk scores to improve patient outcomes through targeted interventions, including treatment initiation and intensity, end-of-life care, and hospitalization and mortality risks.

New heart failure guidelines redefine stages of the disease to emphasize prevention, said Biykem Bozkurt, MD, PhD, but more must be done by payers to identify those at high risk.

Martha Gulati, MD, MS, kicked off the symposium “Saving the Hearts of Women Through Prevention” ahead of the 2022 Congress of the American Society for Preventive Cardiology, which took place Friday through Sunday in Louisville, Kentucky.

Ty J. Gluckman, MD, FACC, FAHA, who is medical director of the Center for Cardiovascular Analytics, Research, and Data Science at Providence St. Joseph Health in Portland, Oregon, addressed the 2022 Congress of the American Society for Preventive Cardiology meeting in Louisville, Kentucky.

Medicare beneficiaries with heart failure who are Black or female were less likely to receive a left ventricular assist device (LVAD) implantation compared with White and male beneficiaries.

Long-term exposure to traffic-related air pollution was linked with higher annual emergency department and outpatient health care costs for older patients, particularly those with cardiovascular disease.

This new study investigated the impact of overly restrictive salt-intake guidelines on patients living with heart failure with preserved ejection fraction (HFpEF), because despite accounting for half of all HF cases, this patient population is often excluded from studies in the space.

Panelists in Wednesday’s webinar, “Don’t Skip Her Beat,” addressed gender disparities in heart failure treatment and offered advice for how women can seek the best care.

The cost avoidance of heart failure–related hospitalizations and emergency department visits may outweigh the additional drug cost in Medicaid members adherent to sacubitril/valsartan.

Few data exist on how right ventricular fractional area change (RVFAC) may contribute to outcomes among patients hospitalized for heart failure, so that potential relationship was investigated in this new study from Japan.

Using chronotropic response as a reference, study authors from Japan investigated the potential influence of exercise-induced heart rate on cardiac output reserve and exercise capacity among a cohort of patients with heart failure with preserved ejection fraction (HFpEF).

Investigators from Toronto compared morbidity and mortality outcomes among patients with acute decompensated heart failure (ADHF) before and during the COVID-19 pandemic.

Using the Nationwide Inpatient Database for trends studied between 1993 and 2011, investigators from Columbia University Irving Medical Center evaluated hospitalization outcomes among patients with heart failure and comorbid gout.

In this study, Italian investigators evaluated how sacubitril/valsartan (Sac/Val) dose titration among older patients with heart failure with reduced ejection fraction (HFrEF) might affect reverse cardiac remodeling and if the success of up-titration can be predicted.

Outcomes in this new study, conducted among patients with chronic heart failure (CHF) on maintenance dialysis and receiving sacubitril/valsartan, were evaluated as they pertained to heart function and blood pressure.

The primary outcomes of this secondary analysis of the MOTIVATE-HF study were improvement in caregiver self-efficacy while caring for patients living with heart failure and caregiver contributions to self-care for these patients following motivational interviewing.

The long-term study also found persistent residual risk of heart failure even after smoking cessation

This new study, which the authors claim is the first to do so, investigated the relationship between COVID-19 vaccination status and survival outcomes among individuals with heart failure.

Sacubitril/valsartan reduced mean pulmonary artery pressure (mPAP) and improved lung congestion, functional capacity, and quality of life in a subset of patients with heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF-PH) using a remote monitoring platform.

This new study, from Taiwan, investigated how menopause affects ventricular structure and function and its possible impact on heart failure among women.

Thirst outcomes were investigated among patients with stable heart failure (HF), due to the limited data available on this relationship and how it, along with fluid and sodium intake, influences clinical outcomes in this population.

This study evaluated levels of 4 biomarkers associated with heart failure with reduced ejection fraction (HFrEF) before and after treatment with the angiotensin receptor neprilysin inhibitor sacubitril/valsartan.